Phase 2 trial demonstrates therapeutic efficacy of guselkumab and golimumab in ulcerative colitis, highlighting potential for advanced combination treatment.
Guselkumab has demonstrated efficacy across all endpoints with a favorable safety profile. No direct comparisons are available between individual IL-23 antagonists or with ustekinumab, the IL-12/23 antagonist, which limits decision-making in clinical practice. Combining two biologics as advanced combination treatment is an attractive strategy to break the therapeutic efficacy ceiling in UC - a proof-of-concept phase 2 trial combining guselkumab and golimumab has shown promise, the combination is currently undergoing evaluation in a larger ongoing trial.
No takes yet. Share an insight, caveat, or question.
Hanžel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: